Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quinolone antibiotic labeling to include warnings of potential tendon inflammation/rupture.

Executive Summary

QUINOLONE MANUFACTURERS AGREE TO TENDONITIS/RUPTURE WARNING IN LABELING following a year of negotiations with FDA. Letters from FDA requesting that labeling changes reflect the potential for fluoroquinolone antibiotics to cause tendonitis or tendon rupture were first sent to the five manufacturers in April 1995. Although several companies initially protested the change, according to FDA, all had submitted approved labeling changes by June.

You may also be interested in...



Seeking Stronger Antibiotic Warnings, Public Citizen Sues FDA

The success of a Public Citizen lawsuit may hinge on whether the advocacy group can convince a judge that 16 months is an "unreasonable delay" in acting on a petition requesting labeling changes

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS028656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel